Chronic Paronychia

Stone, Orville J.

doi:10.1001/archderm.1962.01590090066015

Search citation statements

Order By: Relevance

Paper Sections

Select...

Onychomycosis (With or Without Paronychia):-1

Paronychia1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1963

2021

Publication Types

Select...

Article6

Other1

Relationship

Self Cite1

Independent6

Authors

Journals

Cited by 30 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maximum incidence of paronychia is seen between 30 to 39 years of age in our study which is similar to that observed by Esteves et al [13] who reported increased incidence of paronychia between ages 30 to 60. According to Stone et al [15], paronychia may be seen in children due to thumb sucking but in our study, no children presented with paronychia.…”

Section: Onychomycosis (With or Without Paronychia):-contrasting

confidence: 64%

To Study Nail Changes in Dermatology.

Mishra¹,

Saraswat²

2017

IJAR

View full text Add to dashboard Cite

Section: Onychomycosis (With or Without Paronychia):-contrasting

confidence: 64%

To Study Nail Changes in Dermatology.

Mishra¹,

Saraswat²

2017

IJAR

View full text Add to dashboard Cite

“…Histological studies reveal diffuse, dense, uniform plasma cell infiltrate of the upper dermis. Chronic, untreated cases may lead to osteomyelitis [29,33,34].…”

Section: Paronychiamentioning

confidence: 99%

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Luca¹,

Miron²,

Trandafir³

et al. 2021

Rom J Morphol Embryol

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most frequent pediatric benign vascular tumors, with a reported incidence of 5% to 10%. They have self-limiting evolution pattern divided into a growth phase in the first 12 months and a regression one, that may take up to 10 years. Occasionally, hemangiomas might lead to local or systemic complications, depending on their morphological characteristics. The first line of treatment is β-blockers, such as Propranolol, Timolol, Nadolol, administered either locally or systemically. Newer therapeutic strategies involving laser therapy and angiotensin-converting enzyme inhibitors are being studied, while older treatment modalities like corticosteroids, Imiquimod, Vincristine, Bleomycin and Interferon-α have become second line therapy options. Before establishing the appropriate treatment, clinical, histological, and imaging investigations are required.

show abstract